EP1180122A4 - STRUCTURAL MODELS FOR CYTOPLASMATIC DOMAINS OF TRANSMEMBRANE RECEPTORS - Google Patents

STRUCTURAL MODELS FOR CYTOPLASMATIC DOMAINS OF TRANSMEMBRANE RECEPTORS

Info

Publication number
EP1180122A4
EP1180122A4 EP00936458A EP00936458A EP1180122A4 EP 1180122 A4 EP1180122 A4 EP 1180122A4 EP 00936458 A EP00936458 A EP 00936458A EP 00936458 A EP00936458 A EP 00936458A EP 1180122 A4 EP1180122 A4 EP 1180122A4
Authority
EP
European Patent Office
Prior art keywords
cytoplasmic domains
transmembrane receptors
structural models
models
transmembrane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00936458A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP1180122A1 (en
Inventor
Mark H Ginsberg
Martin Pfaff
Shouchun Liu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GINSBERG, MARK H.
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP1180122A1 publication Critical patent/EP1180122A1/en
Publication of EP1180122A4 publication Critical patent/EP1180122A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70546—Integrin superfamily
    • C07K14/7055—Integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/20—Screening for compounds of potential therapeutic value cell-free systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Microbiology (AREA)
  • Vascular Medicine (AREA)
  • Physics & Mathematics (AREA)
EP00936458A 1999-06-01 2000-06-01 STRUCTURAL MODELS FOR CYTOPLASMATIC DOMAINS OF TRANSMEMBRANE RECEPTORS Withdrawn EP1180122A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US32344799A 1999-06-01 1999-06-01
US323447 1999-06-01
PCT/US2000/015153 WO2000073342A1 (en) 1999-06-01 2000-06-01 Structural models for cytoplasmic domains of transmembrane receptors

Publications (2)

Publication Number Publication Date
EP1180122A1 EP1180122A1 (en) 2002-02-20
EP1180122A4 true EP1180122A4 (en) 2003-03-26

Family

ID=23259240

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00936458A Withdrawn EP1180122A4 (en) 1999-06-01 2000-06-01 STRUCTURAL MODELS FOR CYTOPLASMATIC DOMAINS OF TRANSMEMBRANE RECEPTORS

Country Status (5)

Country Link
EP (1) EP1180122A4 (ja)
JP (1) JP2003504308A (ja)
AU (1) AU765990B2 (ja)
CA (1) CA2374133A1 (ja)
WO (1) WO2000073342A1 (ja)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006112738A1 (en) * 2005-04-19 2006-10-26 Auckland Uniservices Limited Novel peptides and methods for the treatment of inflammatory disorders
WO2008061563A1 (de) * 2006-11-22 2008-05-29 Aplagen Gmbh Peptide für die behandlung der multiplen sklerose

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
ALLMAN R ET AL: "The alphavbeta3 integrin as a molecular target for anticancer drug design", EUROPEAN JOURNAL OF CANCER, PERGAMON PRESS, OXFORD, GB, vol. 33, September 1997 (1997-09-01), pages S173, XP004283621, ISSN: 0959-8049 *
HEMLER M E ET AL: "Functional role for integrin alpha subunit cytoplasmic domains.", COLD SPRING HARBOR SYMPOSIA ON QUANTITATIVE BIOLOGY, vol. 57, 1992, Meeting;Cold Spring Harbor, New York, USA; May 27-June 3, 1992, 1992 Cold Spring Harbor Laboratory Press 10 Skyline Drive, Plainview, New York 11803, USA, pages 213 - 220, XP009004544, ISSN: 0-87969-064-X *
HUGHES PAUL E ET AL: "Suppression of integrin activation: A novel function of a Ras/Raf-initiated MAP kinase pathway.", CELL, vol. 88, no. 4, 1997, pages 521 - 530, XP001121118, ISSN: 0092-8674 *
MUIR TOM W ET AL: "Design and chemical synthesis of a neoprotein structural model for the cytoplasmic domain of a multisubunit cell-surface receptor: Integrin alpha-IIb-beta-3 (platelet GPIIb-IIIa)", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, EASTON, PA, US, vol. 33, no. 24, 1994, pages 7701 - 7708, XP002144665, ISSN: 0006-2960 *
See also references of WO0073342A1 *
THOMAS SHEILA M ET AL: "Specific and redundant roles of Src and Fyn in organizing the cytoskeleton.", NATURE (LONDON), vol. 376, no. 6537, 1995, pages 267 - 271, XP001135012, ISSN: 0028-0836 *
WILLIAMS MICHAEL J ET AL: "The inner world of cell adhesion: Integrin cytoplasmic domains.", TRENDS IN CELL BIOLOGY, vol. 4, no. 4, 1994, pages 109 - 112, XP009004580, ISSN: 0962-8924 *

Also Published As

Publication number Publication date
WO2000073342A1 (en) 2000-12-07
JP2003504308A (ja) 2003-02-04
AU765990B2 (en) 2003-10-09
EP1180122A1 (en) 2002-02-20
AU5177300A (en) 2000-12-18
CA2374133A1 (en) 2000-12-07

Similar Documents

Publication Publication Date Title
EP1224173A4 (en) PYRAZOLE DERIVATIVES AS CANNABINOID RECEPTOR ANTAGONISTS
IL149096A0 (en) Positive modulators of nicotinic receptor agonists
AU3764300A (en) Invertebrate biogenic amine receptors
EP1100960A4 (en) BIVALENT BINDING MOLECULES OF 7 TRANSMEMBRANG PROTEIN COUPLED RECEPTORS
SG80041A1 (en) Muscarinic receptor antagonists
PL342692A1 (en) Derivatives of 2-arylethyl-(piperidin-4-ylmethyl)amine as antagonists of muscarinic receptor
PL356990A1 (en) Isoxazolecarboxamide derivatives as alpha1-adrenergic receptor antagonists
HK1047036A1 (zh) 用於治療偏頭痛的選擇性iglur5，受體拮抗劑
IL149098A0 (en) Positive modulators of nicotinic receptor agonists
EP1157038A4 (en) CLONING OF A P2Y-LIKE 7TM RECEPTOR (AXOR17)
HK1042099A1 (zh) 人g-蛋白偶聯受體
AU2001238178A1 (en) Seven-transmembrane proteins/g-protein coupled receptors
EP1157097A4 (en) GALANINE RECEPTOR-LIKE G-PROTEIN-COUPLED RECEPTOR
IL196053A0 (en) Novel human g-protein coupled receptor
IL148515A0 (en) Human g-protein coupled receptor
EP1180122A4 (en) STRUCTURAL MODELS FOR CYTOPLASMATIC DOMAINS OF TRANSMEMBRANE RECEPTORS
AU5168800A (en) Structural models for cytoplasmic domains of transmembrane receptors
EP1233981A4 (en) RECEPTOR COUPLED TO A G-PROTEIN
AU2773595A (en) Structural models for cytoplasmic domains of transmembrane receptors
AU2162000A (en) Seven transmembrane domain receptor zsig56
EP1120426A4 (en) G-PROTEIN-COUPLED RECIPES
AU1566499A (en) Imidazol derivatives as muscarinic m3 receptor antagonists
EP1680101A4 (en) DEVELOPMENT OF NEW SELECTIVE OESTROGEN RECEPTOR MODULATORS
IL146280A0 (en) Cyclocarbamate derivatives as progesterone receptor modulators
AU4374297A (en) Methods of testing antagonists for their abilities to affect the activity of g protein-coupled receptors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011206

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: GINSBERG, MARK H.

A4 Supplementary search report drawn up and despatched

Effective date: 20030211

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20050204